Focus: Tenpoint Therapeutics is a public UK-based biotech company focused on vision-restoring therapies in ophthalmology. The company is in active commercialization phase with recent partnerships to expand market reach.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Stable — net +4 jobs in 30d
5 added, 1 removed. Backfill posture.
Tenpoint is a high-risk, high-reward opportunity for commercially-minded professionals willing to bet on a single marketed asset in a specialized field.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tenpoint Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tenpoint Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease.
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19.